Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada
Tóm tắt
Among women with epithelial ovarian cancer (EOC), histotype is one of the major prognostic factors. However, few data are available on histotype- specific survival and mortality estimates among these patients. We therefore examined survival and causes of death among women with EOC by histotype. A population- based cohort including all ovarian cancer patients diagnosed in British Columbia (BC) between 1990 and 2014 was built using population-based administrative datasets. We compared causes of death within histotypes, by age at diagnosis, BRCA status, and time since diagnosis. A total of 6975 women were identified as having been diagnosed with EOC between 1990 and 2014 in BC. The most common cause of death among these women was ovarian cancer until 10 years post diagnosis when other causes surpassed ovarian cancer as the leading cause of death. Among women with serous EOCs, ovarian cancer was the leading cause of death 12 years after diagnosis, whereas ovarian cancer was the leading cause of death for 8 years among women with non- serous EOCs. Among women with serous EOCs, ovarian cancer was the leading cause of death for 12 years among younger women (< 60 years of age) compared to 8 years among women > = 60 years of age, and those with BRCA mutations were more likely to die from ovarian cancer than those without a BRCA mutation. Within 10 years from diagnosis, ovarian cancer is the leading cause of death among women diagnosed with EOC.
Tài liệu tham khảo
Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2014 - Special Topic: Skin Cancers. Canadian Cancer Society; 2014. http://www.cancer.ca/. Accessed 20 May 2017.
Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2016 - Special topic: HPV-associated cancers; 2016. http://www.cancer.ca/. Accessed 20 May 2017.
Nuttall R. Canadian cancer statistics 2017. Canadian Cancer Society; 2017. http://www.cancer.ca/. Accessed 20 July 2017.
Gérvas J. Ovarian cancer screening: could you recommend it? No. EBM 2016; doi: https://doi.org/10.1136/ebmed-2016-110385.
Dinkelspiel HE, Champer M, Hou J, et al. Long-term mortality among women with epithelial ovarian cancer. Gynecol Oncol. 2015. https://doi.org/10.1016/j.ygyno.2015.06.005.
Colzani E, Liljegren A, Johansson ALV, et al. Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. JOC 2011; doi: https://doi.org/10.1200/JCO.2010.32.6462.
Van Hemelrijck M, Folkvaljon Y, Adolfsson J, et al. Causes of death in men with localized prostate cancer: a nationwide, population-based study. BJU Int. 2016. https://doi.org/10.1111/bju.13059.
Massa ST, Osazuwa-Peters N, Christopher KM, et al. Competing causes of death in the head and neck cancer population. Oral Oncol. 2017. https://doi.org/10.1016/j.oraloncology.2016.12.006.
Janssen-Heijnen MLG, van Erning FN, De Ruysscher DK, Coebergh JWW, Groen HJM. Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis. Ann Oncol. 2015. https://doi.org/10.1093/annonc/mdv061.
Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017. https://doi.org/10.1016/j.bpobgyn.2016.08.006.
Kommoss S, Gilks CB, du Bois A, Kommoss F. Ovarian carcinoma diagnosis: the clinical impact of 15 years of change. Br J Cancer. 2016. https://doi.org/10.1038/bjc.2016.273.
Matz M, Coleman MP, Sant M, et al. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecol Oncol. 2017. https://doi.org/10.1016/j.ygyno.2016.10.019.
Matz M, Coleman MP, Carreira H, Salmerón D, Chirlaque MD, Allemani C. Worldwide comparison of ovarian cancer survival: histological group and stage at diagnosis (CONCORD-2). Gynecol Oncol. 2017. https://doi.org/10.1016/j.ygyno.2016.11.019.
Gilks CB, Ionescu DN, Kalloger SE, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol. 2008. https://doi.org/10.1016/j.humpath.2008.01.003.
Köbel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008. https://doi.org/10.1371/journal.pmed.0050232.
BC cancer agency registry data (2011). Population data BC. BC cancer agency. 2011 http://www.popdata.bc.ca/data. Accessed 20 May 2017.
BC Vital Statistics Agency (2011). Vital statistics deaths. Population data BC BC vital statistics agency (2011). http://www.popdata.bc.ca/data. Accessed 20 May 2017.
British Columbia Ministry of Heath (2011): Consolidation file (MSP registration and premium billing). Population data BC MOH (2011). http://www.popdata.bc.ca/data. Accessed 20 May 2017.
Hanley GE. Equity in the use and financing of medicines in British Columbia before and after the move to income-based pharma care. 2011. https://open.library.ubc.ca. Accessed 10 December 2017.
About popdata. https://www.popdata.bc.ca/. Accessed 16 April 2017.
RStudio team (2016). RStudio: Integrated development for R. RStudio, inc., boston, MA URL http://www.rstudio.com/. Accessed 17 May 2017.
Gangi A, Cass I, Paik D, et al. Breast cancer following ovarian cancer inBRCAMutation carriers. JAMA Surg. 2014. https://doi.org/10.1001/jamasurg.2014.1081.
McGee J, Giannakeas V, Karlan B, et al. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: is preventive mastectomy warranted? Gynecol Oncol. 2017. https://doi.org/10.1016/j.ygyno.2017.02.032.
Kotsopoulos J, Narod SA. Prophylactic mastectomy for BRCA mutation carriers after ovarian cancer treatment: is it beneficial? Expert Rev Anticancer Ther. 2018. https://doi.org/10.1080/14737140.2018.1424547.
Köbel M, Bak J, Bertelsen BI, et al. Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology. 2014. https://doi.org/10.1111/his.12349.
Vierkoetter KR, Ayabe AR, VanDrunen M, Ahn HJ, Shimizu DM, Terada KY. Lynch syndrome in patients with clear cell and endometrioid cancers of the ovary. Gynecol Oncol. 2014. https://doi.org/10.1016/j.ygyno.2014.07.100.
Schrader KA, Hurlburt J, Kalloger SE, et al. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Obstet Gynecol. https://doi.org/10.1097/AOG.0b013e31825f3576.
Hanley GE, McAlpine JN, Miller D, et al. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention. BMC Cancer. 2018. https://doi.org/10.1186/s12885-018-4153-8.